Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981201 · ClinicalTrials.gov registry record · Phase 3
Celecoxib as a Chemopreventive Agent in Current and Former Smokers
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT00981201: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00981201 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 219 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00981201, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is: * To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. * To examine the toxicity associated with celecoxib administration. * To measure the effect of celecoxib treatment on arachidonic acid metabolites in the bronchial epithelium of current and former smokers.
Interventions
- DRUG Placebo
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
What the finished NCT00981201 record still lists
NCT00981201 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00981201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00981201 about?
NCT00981201 is a clinical study titled "Celecoxib as a Chemopreventive Agent in Current and Former Smokers". The purpose of this study is: * To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. * To examine the toxicity associated with celecoxib administration. * To measure the effect of celecoxib treat...
What is the current status of trial NCT00981201?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2001-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00981201?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00981201?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00981201's enrollment target sits among peer trials
219 1329th of 2000 higher than 670 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia